Eisai, Bristol Myers Squibb enter collaboration for Eisai’s MORAb-202 antibody-drug conjugate
The companies are planning to move into the registrational stage of development for this asset as early as next year
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.